Prosecution Insights
Last updated: November 04, 2026
Application No. 18/292,187

COMPOSITIONS AND METHODS FOR INHIBITING COMPLEMENT FACTOR B

Non-Final OA §103§112
Filed
Mar 10, 2024
Priority
Jan 20, 2022 — provisional 63/301,454 +2 more
Examiner
YU, DELPHINUS DOU YI
Art Unit
1636
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Astrazeneca Ireland Limited
OA Round
1 (Non-Final)
38%
Grant Probability
At Risk
1-2
OA Rounds
2m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants only 38% of cases
38%
Career Allowance Rate
3 granted / 8 resolved
-22.5% vs TC avg
Strong +71% interview lift
Without
With
+71.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
43 currently pending
Career history
51
Total Applications
across all art units

Statute-Specific Performance

§101
5.9%
-34.1% vs TC avg
§103
33.1%
-6.9% vs TC avg
§102
11.0%
-29.0% vs TC avg
§112
36.8%
-3.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 8 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Application Status This action is written in response to applicant’s correspondence received on 03/10/2025. Claims 1, 8, 10, 11, 66, 67, 75, 77, 78, 82, 83, 90, 95-102 are currently pending. Information Disclosure Statement The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered. Priority Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. This application is a 371 of PCT/US2023/011200 filed on 01/20/2023, claiming priority to PRO 63/328,629 filed on 04/07/2022 and PRO 63/301,454 filed on 01/20/2022. Claim Objections Claims 96 & 97 are objected to because of the following informalities: “clam” should be “claim”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 8, 10, 11, 66, 67, 75, 77, 78, 82, 83, 90, 95-102 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claims 1 and 83, it is noted that the claims recite “the antisense strand comprises a region of complementarity to a CFB mRNA target sequence of SEQ ID NO: 13 or 14, and wherein the region of complementarity is at least 20 contiguous nucleotides in length”, once in claim 1, and in each alternative steps i) and ii) of claim 83. This language is considered to be indefinite because both SEQ ID NOs: 13 & 14 are 19nt in length. A person of ordinary skill in the art (PHOSITA) would not be appraised of the metes and bounds of the claims. Regarding claim 97, the phrase "e.g." renders the claim indefinite because it is unclear whether the limitation following the phrase is part of the claimed invention. See MPEP § 2173.05(d). Claims 8, 10, 11, 66, 67, 75, 77, 78, 82, 90, 95-102 are also rejected for depending from a rejected claim 1 but failing to remedy the indefiniteness therein. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 8, 10, 11 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. PNG media_image1.png 448 835 media_image1.png Greyscale As evidenced by FIG. 2D (see below), the sequences of the claimed RNAi oligonucleotide, or a pharmaceutically acceptable salt thereof in claim 1, wherein the sense strand comprises a nucleotide sequence as set forth in SEQ ID NO: 37 and the antisense strand comprises a nucleotide sequence as set forth in SEQ ID NO: 38, inherently meets the claim limitations of claims 8, 10, 11., e.g. “a stem loop set forth as S1-L-S2, wherein S1 is complementary to S2, and wherein L forms a loop between S1 and S2 of 3-5 nucleotides in length” of claim 8, or “wherein L is a tetraloop” of claim 10, or “wherein the tetraloop comprises nucleic acid sequence of GAAA” of claim 11. Hence, claims 8, 10, 11 fail to further limit the scope of claim 1. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Interpretation To advance prosecution, claims 1 and 83 are interpreted to recite “at least 19 contiguous nucleotides in length”. Under the broadest reasonable interpretation (BRI) consistent with the specification, the phrase "nucleotide sequence as set forth in SEQ ID NO: 37" and "nucleotide sequence as set forth in SEQ ID NO: 38" is interpreted to refer to the base sequences as recited in the ST.26 sequence listing, without importing the sugar, base, or internucleotide modifications annotated in the feature table. ST.26 represents modified residues by their parent base letter in the residue string with chemical modifications recorded separately in the feature table; accordingly, "as set forth in" SEQ ID NOs: 37 and 38 encompasses those base sequences with any modification scheme, including no modifications. Claim 1 has been examined under this interpretation. Applicant is invited to clarify whether the recitation "as set forth in SEQ ID NO: 37 or 38" is intended to incorporate the specific nucleoside and internucleotide modifications of the sequence listing feature table. If so, applicant should amend the claim language to expressly recite those modifications, as such an amendment would be examined on its merits upon entry. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 8, 10, 11, 66, 67, 75, 77, 78, 82, 83, 90, 95-102 are rejected under 35 U.S.C. 103 as being unpatentable over McIninch (US11965166B2, issued on 04/23/2024, has priority to PRO63/273,215 on 10/29/2021), in view of Koser (WO2019079781A2, published on 04/25/2019), further in view of Elbashir (EMBO J. 2001;20(23):6877-88). McIninch (2021) teaches an RNAi oligonucleotide for reducing complement factor B (CFB) expression, compound AD-1724698 (Col 135, Table 2) and AD-1726934 (Col 155, Table 2) with sequences set forth in SEQ ID NO: comprising a sense (SEQ ID NO: 44, 21nt, ACAAUGUGAGUGAUGAG AUCU) and an antisense strand (SEQ ID NO: 437, 21nt, AGAUCUCAUCACUCACAUUGUAG), wherein both form a duplex region, wherein the antisense strand comprises a region of complementarity to a CFB mRNA target sequence of SEQ ID NO: 14, see alignment below. As interpreted above, the region of complementarity is 19 contiguous nt in length, as is SEQ ID NO: 14, which matches the claimed region of complementary sequence. Query 1: Instant SEQ ID NO: 14 acaatgtgagtgatgagat Query 2: McIninch SEQ ID NO: 44 5’- ACAAUGUGAGUGAUGAGAUCU -3’ ||||||||||||||||||| Sbjct: McIninch SEQ ID NO: 437 3’- GAUGUUACACUCACUACUAGA -5’ McIninch further teaches 7 selected compounds with the same 19nt target regions in the CFB mRNA with full modifications (AD-1724691-1724693, AD-1724695, AD-1724698-1724700; Col 176-Col 177, Table 3; see screenshot below), indicating that the claimed target region set forth in the claimed SEQ ID NO: 14 is a known “hotspot” for developing effective RNAi agents against CFB. PNG media_image2.png 391 1429 media_image2.png Greyscale McIninch does not teach “wherein the sense strand comprises a nucleotide sequence as set forth in SEQ ID NO: 37, the antisense strand comprises a nucleotide sequence as set forth in SEQ ID NO: 38”. However, Koser (2019) discloses nicked GalXC tetraloop architecture comprising: a 36-nt sense strand having a 5' duplex region followed by a 3' stem-loop of the structure S1-L-S2, wherein S1 is 5'-GCAGCC-3', L is the GAAA tetraloop, and S2 is 5'-GGCUGC-3' (Page 6, ¶[00018]; FIG. 10); a 22-nt antisense strand comprising a 19-nt complementary core, a non-complementary 5' nucleotide, and a GG 3' overhang; three monovalent GalNAc moieties individually conjugated to each adenosine of the GAAA loop for ASGPR-mediated hepatocyte delivery; and stabilizing 2'-OMe and 2'-F modifications with phosphorothioate linkages (Page 50, ¶[000174]; FIG. 10; Claims 23-24). Koser further teaches that " In some embodiments, a stem-loop provides the molecule better protection against degradation (e.g., enzymatic degradation) and facilitates targeting characteristics for delivery to a target cell… a loop provides added nucleotides on which modification can be made without substantially affecting the gene expression inhibition activity of an oligonucleotide" (Page 27, ¶[00103], lines 4-8). Elbashir (2001) teaches that the canonical RISC-active element of an siRNA duplex is a 19-nt base-paired region and that the most potent siRNA duplexes are 21 nt in length comprising a 19-nt complementary core with 2-nt 3' overhangs (Page 6877, Abstract, lines 8-10; Page 6879, Figure 2C, bottom panel). This confirms that reformatting a validated guide sequence into the GalXC nicked-tetraloop architecture taught by Koser preserves the functionally active region intact. Regarding claims 1, 8, 10, 11, it would have been obvious for a PHOSITA before the effective filing date of the claimed invention to have modified the siRNA duplex of McIninch, AD-1724698 or AD-1726934 (symmetrical 21nt duplex with 2nt overhangs on 3’ ends of both strands set forth in SEQ ID NO: 44 and SEQ ID NO: 437), by preserving the 19nt complementary region of the duplex that targets the CFB mRNA region as claimed set forth in the claimed SEQ ID NO: 14 based on Elbashir’s discovery that 19nt complementary region with 2nt overhang designs are the most potent RNAi design, and explored replacing the 3’ overhang of the sense strand (CU dinucleotide in McIninch’s SEQ ID NO: 44) with the sense strand 3’ end GalXC S1-L-S2 scaffold and stemloop architecture of Koser. It would have merely amounted to a simple substitution of interchange-able prior art elements according to known methods to yield predictable results. One would have been motivated to do so because Koser teaches advantages of the GalXC stemloop architecture such as “better protection against degradation” and “facilitates targeting characteristics for delivery”. One would have reasonable expectations of success because Koser teaches that “… loop provides added nucleotides on which modification can be made without substantially affecting the gene expression inhibition activity of an oligonucleotide" (Page 27, ¶[00103], lines 4-8). Regarding claim 66, McIninch further teaches pharmaceutical compositions comprising the claimed dsRNA RNAi agent, or a pharmaceutically acceptable salt thereof in claim 15, and a pharmaceutically acceptable carrier, excipient, or diluent, such as unbuffered or buffered solutions in claims 16-20. Regarding claims 67 and 99, McIninch further teaches “a method of treating a subject having a disorder that would benefit from reduction in complement factor B (CFB) expression. The method includes administering to the subject a therapeutically effective amount of any of the dsRNAs of the invention or any of the pharmaceutical compositions of the invention, thereby treating the subject having the disorder that would benefit from reduction in CFB expression” (Col 9, lines 33-40). Regarding claim 75, both McIninch (Col 9, line 54) and Koser (Page 18, ¶[00080], line 2) teach the subject is a human for the claimed methods. Regarding claims 77 and 78, McIninch further teaches a range of diseases, disorders, or conditions mediated by complement pathway activation or dysregulation (Col 8, line 31-Col 9, line 21) that includes Rheumatoid Arthritis (Col 9, lines 3-4). Regarding claim 82, McIninch further teaches the RNAi oligonucleotide, or a pharmaceutically acceptable salt thereof, is administered at a dose of between about 0.01 mg/kg to about 50 mg/kg (Col 9, lines 55-56), which overlaps the range of about 0.1 mg/kg to about 150 mg/kg. Regarding claim 83, McIninch further teaches a method of reducing CFB expression in a cell (Col 7, lines 62-67), or in a subject (Col 9, lines 35-40) the method includes contacting the cell with the claimed dsRNA agent in claim 1 or administering the dsRNA agent of claim 1 to a subject in need thereof. The sequences and target mRNA sequence region are discussed above regarding claim 1. Regarding claim 90, McIninch further teaches kits comprising the claimed RNAi agent or pharmaceutically acceptable salt thereof (Col 10, lines 51-54). Regarding claim 95, McIninch further teaches the RNAi agent is a pharmaceutically acceptable salt thereof (Col 10, lines 58-67). Regarding claim 96, McIninch further teaches that the pharmaceutical composition, “wherein the buffer solution comprises acetate, citrate, …, or phosphate or any combination thereof” (Claim 19). Regarding claims 97 and 98, McIninch further teaches that “Pharmaceutically acceptable salts" of each of RNAi agents herein include, but are not limited to, a sodium salt, a calcium salt, a lithium salt, a potassium salt, an ammonium salt, a magnesium salt, and mixtures thereof” (Col 10, lines 59-62). Regarding claim 100, Koser further teaches “… the oligonucleotides of the instant disclosure would typically be administered quarterly (once every three months), bi-monthly (once every two months), monthly, or weekly. For example, the oligonucleotides may be administered every one, two, or three weeks. The oligonucleotides may be administered daily” (Page 46, ¶[000163]). Regarding claim 101, Koser further teaches “…Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration…” (Page 41, ¶[000148]). Regarding claim 102, in addition to Koser’s teaching above, McIninch also teaches subcutaneous route as one alterative of “depot injection” to reduce administration frequency (Col 123, lines 6-15). Conclusion No claims are allowable. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Delphinus D. Yu whose telephone number (571) 272-1576. The examiner can normally be reached Mon-Thr 7:30am to 4:30pm Fri 10am to 2pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Neil P Hammell can be reached on (571) 270-5919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DELPHINUS DOU YI YU/Examiner, Art Unit 1636 /NEIL P HAMMELL/Supervisory Patent Examiner, Art Unit 1636
Read full office action

Prosecution Timeline

Mar 10, 2024
Application Filed
Oct 19, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778136
VIRULENCE FACTOR FSPL GENE FROM SUGARCANE POKKAH BOENG DISEASE AND USE THEREOF
3y 7m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 1 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
38%
Grant Probability
99%
With Interview (+71.4%)
2y 10m (~2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 8 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month